A total of 40 Equity Offering deals (pending and completed) were announced in the Pharmaceuticals of Australia, in the last twelve months resulting in a total deal value of over $5,567.1 million. In the LTM period, December 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $5,058.5 million, resulting in an average deal value of $632.3 million during that month. On the other hand, the month of December 2021 was the most prolific in terms of deal volume, recording a total of 8 deals, resulting in an average deal value of $632.3 million during that month.
Of the 40 deals, the deal secured between Platinum Asset Management Ltd; Platinum International Health Care Fund and HaemaLogix Pty Ltd, was the largest Equity Offering deal in the Australia Pharmaceuticals sector, which was valued at $10.0 million and was completed on September 8, 2021. The second-largest deal was between Merchant Funds Management Pty Ltd and Dimerix Ltd, while the third-largest deal was between Tattarang Pty Ltd and Emyria Ltd. The Merchant Funds Management Pty Ltd-Dimerix Ltd deal and the Tattarang Pty Ltd-Emyria Ltd deal were valued at $7.0 million and $5.0 million, respectively. The fourth-largest deal was between New Life Sciences Capital LLC-Regeneus Ltd valued at $1.2 million
Cumulatively, the top five deals amounted to $23.2 million and accounted for nearly 0.42% of the total deals (by value) announced during the last twelve months.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward